MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Search

DBV Technologies SA

Ouvert

1.312 18.84

Résumé

Variation du prix de l'action

24h

Actuel

Min

1

Max

1.374

Chiffres clés

By Trading Economics

Revenu

2.7M

-30M

BPA

-0.288

Marge bénéficiaire

-2,852.369

EBITDA

5.1M

-29M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+421.74% upside

Dividendes

By Dow Jones

Prochains Résultats

10 avr. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

118M

Ouverture précédente

-17.53

Clôture précédente

1.312

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

DBV Technologies SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 déc. 2024, 23:55 UTC

Actions en Tendance

Stocks to Watch: Adobe, Champions Oncology, DBV Technologies

22 oct. 2024, 21:37 UTC

Principaux Mouvements du Marché

DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch

Comparaison

Variation de prix

DBV Technologies SA prévision

Objectif de Prix

By TipRanks

421.74% hausse

Prévisions sur 12 Mois

Moyen 6 EUR  421.74%

Haut 6 EUR

Bas 6 EUR

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

1 ratings

1

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.87 / 1.228Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Strong Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.